Based on the emerging role of IL6/JACK/STAT3 pathway in dasatinib-resistant HNSCC patients, a phase II clinical trial of combined therapy of cetuximab plus dasatinib in metastatic HNSCC was conducted, measuring pre- and post-treatment patients’ serum levels of Interleukin-6 (IL-6) [98]. The gene discussed is IL6; the disease is head and neck squamous cell carcinoma.